How immune responses can be improved in pancreatic cancer treatment
Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade
This study is looking at how a substance called IL-6 affects pancreatic cancer and its surroundings, and it aims to find out if blocking IL-6 can help boost the immune system's ability to fight the cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10544304 on NIH RePORTER |
What this research studies
This research investigates the role of interleukin-6 (IL-6) in pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer that often resists immune responses. By analyzing patient samples, the study aims to understand how IL-6 influences the behavior of cancer-associated fibroblasts and immune cells in the tumor microenvironment. The researchers will explore the effects of blocking IL-6 and PD-1, an immune checkpoint, to potentially enhance the immune response against the cancer. This innovative approach seeks to reprogram the tumor environment to make it more responsive to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with early-stage pancreatic cancer or those not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy strategies for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promising results in targeting immune checkpoints and cytokines in various cancers, suggesting potential success for this novel approach in pancreatic cancer.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Lesinski, Gregory B. — Emory University
- Study coordinator: Lesinski, Gregory B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.